QD Clinic Podcast - 106 thru 109

Save

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.

In this compilation from the past week we talk about

- HIV and arthritis

- Hyperuricemia in PsA

- An odd kind of dermatomyositis

Check Out the Virtual ACR Playbook

Save

If you need a plan for this weekend's ACR meeting, check out and download our latest, "Virtual ACR 2020 Playbook". The playbook covers: setting virtual learning goals, sessions you probably shouldn't miss, how to still have peer interactions, what to do if you only have time to "dabble' - and more.

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

Save

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

ACR 2020 Your Way - Get Your Topic Emails

Save

ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?

Long-Term Benefits of Ixekizumab in Psoriatic Arthritis

Save

The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well. 

SPARTAN ACR20 Recommendations on Spondyloarthritis

Save

SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.

US Differs from Worldwide Drug Reimbursements

Save

"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine.  US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai

Are Rheums Attending ACR 2020?

Save

ACR 2020 (aka ACR Convergence) is just around the corner, with the opening ceremonies and lecture starting Thursday, November 5th; followed by the full meeting beginning the next morning, Friday November 6th. 

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Abatacept in Early Systemic Sclerosis (ASSET study)

Save

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Save

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis

Save

The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.

Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction

Save

JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.

Vedolizumab Promising in Immune-Related GI Events

Save

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Immune Necrotizing Myopathy

Save

A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.

Telemedicine Outcomes in RA Care

Save

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).

FDA Hearing on COVID-19 Vaccines

Save

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Save

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

High Burnout Rates Among Rheumatologists

Save

Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.